Loading
companiesCompany
Apollomics
Apollomics is a US-Chinese company whose MET inhibitor vebreltinib is approved in China for MET exon 14 lung cancer through its partner Avistone, and whose E-selectin antagonist uproleselan failed in acute myeloid leukaemia in 2024.
Also called: Apollomics Inc.Apollomics (Hangzhou)
Overview
Apollomics, based in Foster City, California with operations in Hangzhou and listed on Nasdaq since a 2023 merger, licenses and develops cancer drugs. Vebreltinib (APL-101, bozitinib), a selective MET inhibitor, is approved in China for MET exon 14 skipping non-small-cell lung cancer via Avistone; the phase 3 trial of uproleselan, an E-selectin antagonist licensed from GlycoMimetics, with chemotherapy in relapsed acute myeloid leukaemia missed its survival endpoint in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Foster City, CA, US
Scorecard
All companies#255of 1244 companies, score 19
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +8
1 approved, 0 in phase 3, 0 earlier, 1 targets, 17 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedOral selective MET tyrosine kinase inhibitor
Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.
Similar pages
- TrialVebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Shares Avistone Biotechnology, Vebreltinib, Non-small-cell lung cancer.
- TrialVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Shares Avistone Biotechnology, Vebreltinib, Non-small-cell lung cancer.
- TrialVebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur
Shares Avistone Biotechnology, Vebreltinib.
- TrialAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
- TrialA Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
- TrialA Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
- TrialA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Shares Vebreltinib, Non-small-cell lung cancer.
- TrialA First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Shares MET, Non-small-cell lung cancer.
cancers
fronts
targets
drugs
ApprovedOral selective MET tyrosine kinase inhibitor